Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Carcinoma, Pancreatic Ductal × contrast agent BR1 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 2 Breast Neoplasms 2 Neoplasm Metastasis 1 Liver Neoplasms 1 Colon Cancer Liver Metastasis 1 Carcinoma, Pancreatic Ductal 1 Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 8 130-nm albumin-bound paclitaxel 5 Albumin-Bound Paclitaxel 4 napabucasin 2 Oxaliplatin 2 MK-4721 2 Leucovorin 2 Fluorouracil 2 Carboplatin 2 tremelimumab 1 irinotecan sucrosofate 1 ensituximab 1 durvalumab 1 contrast agent BR1 1 cc-486 1 Taxes 1 Practice Guidelines as Topic 1 Pancreaticoduodenectomy 1 Paclitaxel 1 PEGPH20 1 Lead 1 Irinotecan 1 Enoxaparin 1 EC regimen 1 Drug Therapy 1 Dexamethasone 1 Cisplatin 1 CP protocol 1 Azacitidine 1 Axitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04146441 2023-01-19

PDAC

St. Olavs Hospital

Phase 2 Completed

Gastrointestinal

Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon ⚡